German drugmaker Bayer acquired all rights the company does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly’s Loxo Oncology.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Philadelphia-based Passage Bio launched with a Series A financing round valued at $115.5 million, led by OrbiMed Advisors.
5AM Ventures raised a total of $497 million for two more funds.
Axovant Sciences, a clinical-stage company developing innovative gene therapies, today announced the formation of Arvelle Therapeutics and the strategic transition of its legacy small molecule team into the newly formed company.
Ireland’s Teckro, which makes software that allows physicians to take part in drug development trials from mobile devices, has won $25 million in financial backing from investors as the company hatches longer-term plans for a stock market listing.
AstraZeneca forecast sales growth for full-year 2019, driven by revenue from cancer medicines and other new treatments.
Johnson & Johnson plunked down $3.4 billion in cash to acquire privately held Auris Health Inc., a company that has developed robotic endoscopic technologies for the treatment of lung cancer.
The rising costs of prescription medicine took center stage during a hearing held by the Ways and Means Committee in the U.S. House of Representatives.
Navitas Life Sciences Announces Acquisition of DataCeutics to Augment Global Clinical Data Science Services
Navitas Life Sciences, a TAKE Solutions Enterprise, announced that the company will acquire Life Sciences services player DataCeutics in North America.
Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.